Study summary

Combining two bispecific antibodies that hit different targets produced deep responses

Talquetamab plus teclistamab trial · Phase 1b, early · Published January 2025, New England Journal of Medicine

What was tested

Talquetamab (targeting GPRC5D) combined with teclistamab (targeting BCMA), for myeloma that had relapsed after multiple earlier treatments.

What they found

• Responses were deep and frequent, even in people whose myeloma had stopped responding to single-target BCMA therapy.
• Hitting two targets at once may help prevent the cancer from escaping treatment.

What it means

Supports combining bispecific antibodies with different targets; larger trials are testing this in earlier lines.